Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9716647 | 0.92 | HTT (0.74) | HTTACHESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL7141111 | 0.84 | HTT (0.63) | HTTACHESMN1; SMN2LMNACNR2 | |
| Bicarbonate SCHEMBL7274222 | 0.84 | HTT (0.55) | HTTACHESMN1; SMN2LMNACNR2 | |
| SCHEMBL2724136 | 0.83 | HTT (0.71) | HTTACHESMN1; SMN2LMNACNR2 | |
| SCHEMBL8303697 | 0.83 | HTT (0.61) | HTTACHESMN1; SMN2LMNACNR2 | |
| SCHEMBL3482861 | 0.82 | HTT (0.65) | HTTACHESMN1; SMN2LMNACNR2 | |
| SCHEMBL7913005 | 0.79 | HTT (0.45) | HTTACHESMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL28705768 | 0.78 | HTT (0.53) | HTTACHESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL20218939 | 0.77 | CNR2 (0.75) | HTTACHESMN1; SMN2LMNACNR2 | |
| SCHEMBL20210693 | 0.77 | CNR2 (0.57) | HTTACHESMN1; SMN2LMNACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | claimed |
| US-20130224855-A1 | CULTURE MEDIUM FOR EUKARYOTIC CELLS | FRIESLANDCAMPINA NEDERLAND HOLDING B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| EP-2611904-A2 | CULTURE MEDIUM FOR EUKARYOTIC CELLS | Friesland Brands B.V. (NL) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030217-A2 | CULTURE MEDIUM FOR EUKARYOTIC CELLS | FRIESLAND BRANDS B.V. (NL) | 2012-03-08 | — | — | WO | disclosed |
| US-20050255138-A1 | Active agent transport systems | MHR INSTITUTIONAL PARTNERS IIA LP | 2005-11-17 | — | — | US | disclosed |
| US-6916489-B2 | Active agent transport systems | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1021169-A4 | ACTIVE AGENT TRANSPORT SYSTEMS | EMISPHERE TECH INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030133953-A1 | Active agent transport systems | EMISPHERE TECHNOLOGIES, INC. | 2003-07-17 | — | — | US | disclosed |
| US-6348207-B1 | EXPOSING BIOLOGICALLY ACTIVE AGENT TO COMPLEXING PERTURBANT TO REVERSIBLY TRANSFORM BIOLOGICALLY ACTIVE AGENT TO INTERMEDIATE STATE AND FORM ORALLY DELIVERABLE SUPRAMOLECULAR COMPLEX, ORALLY ADMINISTERING COMPLEX TO SUBJECT | EMISIPHERE TECHNOLOGIES, INC. | 2002-02-19 | — | — | US | disclosed |
| WO-1998025589-A1 | ACTIVE AGENT TRANSPORT SYSTEMS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0758843-A4 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | EMISPHERE TECH INC (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5714167-A | REVERSIBLY FORMING SUPRAMOLECULAR COMPLEX OF ACTIVE AGENT WITH PERTURBANT; DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5629020-A | Modified amino acids for drug delivery | EMISPHERE TECHNOLOGIES, INC. (US) | 1997-05-13 | — | — | US | disclosed |
| EP-0758843-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | Emisphere Technologies, Inc. (US) | 1997-02-26 | — | — | EP | disclosed |
| WO-1995028838-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050255138-A1 | Active agent transport systems | ABCB11, SLC47A1, ABCB4 | HTT 1762/4885ACHE 2942/4885SMN1; SMN2 3349/4885 |
| US-20030133953-A1 | Active agent transport systems | ABCB11, SLC47A1, ABCB4 | HTT 1762/4885ACHE 2942/4885SMN1; SMN2 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.